- Home
- XBIO vs QNRX Comparison
XBIO vs QNRX Comparison
Compare XBIO & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- QNRX
- Stock Information
- Founded
- XBIO N/A
- QNRX 2018
- Country
- XBIO United States
- QNRX United States
- Employees
- XBIO N/A
- QNRX 3
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- XBIO Health Care
- QNRX Health Care
- Exchange
- XBIO Nasdaq
- QNRX Nasdaq
- Market Cap
- XBIO 4.4M
- QNRX 4.8M
- IPO Year
- XBIO N/A
- QNRX N/A
- Fundamental
- Price
- XBIO $3.27
- QNRX $8.59
- Analyst Decision
- XBIO Hold
- QNRX
- Analyst Count
- XBIO 1
- QNRX 0
- Target Price
- XBIO N/A
- QNRX N/A
- AVG Volume (30 Days)
- XBIO 15.4K
- QNRX 107.3K
- Earning Date
- XBIO 11-11-2025
- QNRX 11-06-2025
- Dividend Yield
- XBIO N/A
- QNRX N/A
- EPS Growth
- XBIO N/A
- QNRX N/A
- EPS
- XBIO N/A
- QNRX N/A
- Revenue
- XBIO $2,446,221.00
- QNRX N/A
- Revenue This Year
- XBIO $1.99
- QNRX N/A
- Revenue Next Year
- XBIO $20.00
- QNRX N/A
- P/E Ratio
- XBIO N/A
- QNRX N/A
- Revenue Growth
- XBIO N/A
- QNRX N/A
- 52 Week Low
- XBIO $2.20
- QNRX $5.01
- 52 Week High
- XBIO $5.27
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- XBIO 54.84
- QNRX 70.88
- Support Level
- XBIO $2.97
- QNRX $7.35
- Resistance Level
- XBIO $3.70
- QNRX $7.79
- Average True Range (ATR)
- XBIO 0.23
- QNRX 0.38
- MACD
- XBIO 0.05
- QNRX 0.13
- Stochastic Oscillator
- XBIO 52.75
- QNRX 46.79
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.